Paper · 35658604

Dabrafenib Versus Dabrafenib + Trametinib in BRAF-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial.

Busaidy NL and 14 others. Thyroid, 2022. Cited by 137 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Dabrafenib Versus Dabrafenib + Trametinib in BRAF-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial. Papers, record 35658604. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35658604

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Dabrafenib Versus Dabrafenib + Trametinib in BRAF-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial.; PubMed
Journal: Thyroid; PubMed
Year: 2022; PubMed
Publication types: Randomized Controlled Trial, Multicenter Study, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/35658604/; PubMed
DOI: https://doi.org/10.1089/thy.2022.0115; PubMed
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC9595631/; PubMed
The journal: https://conductscience.org/library/journal-index/9104317; PubMed
Citations, by iCite: 137; iCite
Relative citation ratio, by iCite: 11.8; iCite
Revised in PubMed: 2026-01-27; PubMed

Authors15

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename	ORCID iD
1	Busaidy NL	Naifa L
2	Konda B	Bhavana
3	Wei L	Lai
4	Wirth LJ	Lori J	https://orcid.org/0000-0002-2629-2289
5	Devine C	Catherine
6	Daniels GA	Gregory A
7	DeSouza JA	Jonas A
8	Poi M	Ming
9	Seligson ND	Nathan D
10	Cabanillas ME	Maria E

1 to 10 of 15Source PubMed

See all 15 authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Melanoma	Major topic
Thyroid Neoplasms	Major topic
Adenocarcinoma	Major topic
Humans
Adolescent
Adult
Proto-Oncogene Proteins B-raf
Iodine Radioisotopes
Pyrimidinones
Pyridones
Antineoplastic Combined Chemotherapy Protocols
Oximes
Mutation
Imidazoles

Source PubMed

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes it	Agency	Country	NIH project	Stated by	Source
R01 CA227847	NCI NIH HHS	United States	R01CA227847	PubMed	NIH RePORTER
P30 CA016058	NCI NIH HHS	United States	P30CA016058	PubMed and NIH	NIH RePORTER
P30 CA016672	NCI NIH HHS	United States	P30CA016672	PubMed and NIH	NIH RePORTER

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

Trial	Title	The trial lists it as	Named in the paper's record
NCT01723202	Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer	Results	Yes

Source ClinicalTrials.gov

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References20

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	25,417,114	Integrated genomic characterization of papillary thyroid carcinoma.	Cell	2014	https://conductscience.org/library/papers/25417114	PubMed
2	19,097,774	New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).	Eur J Cancer	2009	https://conductscience.org/library/papers/19097774	PubMed
3	22,805,291	Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.	Lancet Oncol	2012	https://conductscience.org/library/papers/22805291	PubMed
4	27,626,519	Biologic and Clinical Perspectives on Thyroid Cancer.	N Engl J Med	2016	https://conductscience.org/library/papers/27626519	PubMed
5	24,768,112	Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.	Lancet	2014	https://conductscience.org/library/papers/24768112	PubMed
6	18,381,570	BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines.	J Clin Endocrinol Metab	2008	https://conductscience.org/library/papers/18381570	PubMed
7	29,072,975	Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.	J Clin Oncol	2018	https://conductscience.org/library/papers/29072975	PubMed
8	27,080,216	Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.	Lancet Oncol	2016	https://conductscience.org/library/papers/27080216	PubMed
9	28,919,011	Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.	Lancet Oncol	2017	https://conductscience.org/library/papers/28919011	PubMed
10	25,285,888	BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer.	Thyroid	2015	https://conductscience.org/library/papers/25285888	PubMed

1 to 10 of 20

See all 20 references

Cited by95

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 137 citations.

PMID	Title	Journal	Year	In Papers	Source
42,942,330	The Use of Radioactive Iodine in the Treatment of Thyroid Cancer: Novel Aspects.	Life (Basel)	2026	https://conductscience.org/library/papers/42942330	PubMed
42,741,758	How to manage radioiodine-refractory thyroid cancer in the era of precision medicine.	Drugs Context	2026	https://conductscience.org/library/papers/42741758	PubMed
42,676,342	Thirty years of NCI thyroid cancer research investment (1996-2025): a longitudinal portfolio analysis of funding trends, molecular target emphasis and thematic evolution.	Front Oncol	2026	https://conductscience.org/library/papers/42676342	PubMed
42,661,840	Radioiodine-Refractory Differentiated Thyroid Cancer: Definition, Molecular Mechanisms, and Advances in Precision Therapy.	Cancer Innov	2026	https://conductscience.org/library/papers/42661840	PubMed
42,536,275	Encorafenib plus binimetinib for BRAF V600-mutated thyroid cancer in Japan: final analysis.	Int J Clin Oncol	2026	https://conductscience.org/library/papers/42536275	PubMed
42,286,159	Targetable alterations and personalized treatment in ameloblastoma: results from a prospective observational precision oncology study.	NPJ Precis Oncol	2026	https://conductscience.org/library/papers/42286159	PubMed
42,265,770	Loss of CSE couples with BRAF V600E to fuel thyroid cancer metastatic progression through zinc-dependent activation of the EMT machinery.	J Exp Clin Cancer Res	2026	https://conductscience.org/library/papers/42265770	PubMed
42,159,588	Clinical outcomes in older adults with advanced thyroid cancer.	Oncologist	2026	https://conductscience.org/library/papers/42159588	PubMed
42,143,022	Understanding and overcoming innate and acquired MAPK inhibition resistance in anaplastic thyroid cancer.	Cell Rep Med	2026	https://conductscience.org/library/papers/42143022	PubMed
42,128,849	Efficacy and safety of dabrafenib plus trametinib in BRAFV600E-mutated advanced thyroid carcinoma: Real world experience in 37 patients.	Endocr J	2026	https://conductscience.org/library/papers/42128849	PubMed

1 to 10 of 95

See all 95 cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Gene	NCBI Gene ID	Linked by	In Genes
BRAF	673	PubTator's text mining	https://conductscience.org/library/genes/673

Source NCBI Gene

Drugs2

The drugs whose trials, in the Pipelines release, list the paper.

Drug	ChEMBL ID	The trials list it as	Trials	In Drugs and targets	Source
DABRAFENIB	CHEMBL2028663	Results	1	https://conductscience.org/library/drugs/CHEMBL2028663	ChEMBL
TRAMETINIB	CHEMBL2103875	Results	1	https://conductscience.org/library/drugs/CHEMBL2103875	ChEMBL

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/35658604

GET https://conductscience.org/api/papers/v1/35658604/cited_by?page=2

API reference For AI assistants